CASI Pharmaceuticals Stock News

The shares of CASI Pharmaceuticals Inc (NASDAQ: CASI) have received a $3.80 price target by Mizuho. These are the details.

Penny stocks to buy according to top Wall Street analysts The post 3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383% appeared first on Penny Stocks to Buy, Picks, News and Information | Pen

The stock price of CASI Pharmaceuticals, Inc. (Nasdaq: CASI) increased by over 10% pre-market. This is why it happened.

ROCKVILLE, Md. and BEIJING, March 30, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeuti

Investors don't like that the company is hitting up the market for more cash.

ROCKVILLE, Md. and BEIJING, March 24, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutic

ROCKVILLE, Md. and BEIJING, March 23, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics

ROCKVILLE, Md. and BEIJING, March 11, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutic

Cleave Therapeutics Inc has out-licensed CB-5339 to CASI Pharmaceuticals Inc (NASDAQ: CASI) in mainland China, Taiwan, Hong Kong, and Macau. Cleave and CASI will develop CB-5339 in both hematolo

ROCKVILLE, Md., and BEIJING, Dec. 23, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics

ROCKVILLE, Md. and BEIJING, Nov. 18, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics

CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q3 2020 Results - Earnings Call Transcript

CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint rec

Earlier today, CASI issued a press release providing the details of our financial results for the quarter ended June 30, 2020, as well as a corporate and clinical update. The press release is availab

Shares of CASI Pharmaceuticals (NASDAQ:CASI) moved higher by 1.6% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 43.75% year over year to ($0.